We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Urine Dipstick Method Developed for Malaria Diagnosis

By LabMedica International staff writers
Posted on 06 Jun 2016
Print article
Image: The Urine Malaria Test, an immunochromatographic lateral flow assay (Photo courtesy of Fyodor Biotechnologies).
Image: The Urine Malaria Test, an immunochromatographic lateral flow assay (Photo courtesy of Fyodor Biotechnologies).
Malaria is the world’s most important tropical parasitic disease and a leading cause of death worldwide and the disease is caused by the parasite, Plasmodium species and transmitted to humans by infected mosquitoes.

Symptoms include fever and usually appear 10 to 15 days after someone is bitten by an infected mosquito. While easily treated, proper early diagnosis is critical to successful management, since many diseases in tropical areas of the world are characterized by fever, but left untreated the parasites multiply in the liver and can become life-threatening.

A Nigerian scientist and a team at Johns Hopkins University (Baltimore, MD, USA) have developed a Urine Malaria Test (UMT), currently in clinical validation, is indicated for use in individuals who present with fever suspected of being malaria. The UMT, which licensed with exclusive global rights from Johns Hopkins University, incorporates a novel dipstick technology that is ideal for rapid point-of-need diagnosis of clinical malaria from urine instead of blood, and offers significant advantages over microscopy and other malaria diagnostics, which require the use of blood.

The UMT dipstick detects novel Plasmodium proteins shed in the urine of febrile malaria patients and can be performed and read by persons with little or no training. These novel proteins or fragments are not cleaved by any known proteases, are highly immunogenic and elicit early immune response, and thus present as early markers of clinical malaria. The UMT is a sensitive and specific immunochromatographic lateral flow assay, which can be easily performed by an untrained individual using a urine sample.

To perform, the test strip is dropped into a clean container with as little as 100 µL of urine, allowed to flow up the strip for 1 to 2 minutes, and incubated at room temperature for 20 minutes. If two visible lines appear on the strip, the test is positive; if one line appears, the test is negative. The UMT demonstrates equivalent performance compared to commercially available blood-based rapid tests for the diagnosis of clinical malaria, with a limit of detection of 125 parasites/µl, well within the 100 to 200 parasites/µl analytical performance range recommended for malaria rapid diagnostic tests by the World Health Organization (Geneva, Switzerland). The UMT is being manufactured by Fyodor Biotechnologies, Inc (Baltimore, MD, USA).

Related Links:
Johns Hopkins University
World Health Organization
Fyodor Biotechnologies
Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Quality Control Material
Multichem U
New
Multiple Channel Electronic Pipette
MPB Series
New
Integrated Chemistry & Immunoassay System
Dimension RxL Max

Print article

Channels

Molecular Diagnostics

view channel
Image: A new machine rapidly and robustly separates cancer cells from blood samples (Photo courtesy of DGIST)

Centrifugal System for Separating Circulating Tumor Cells from Blood Samples to Improve Cancer Diagnosis

Circulating tumor cells are cells that break off from cancers and are released into the blood stream. They can go on to form the seeds for new tumor formation in other parts of the body, known as metastases.... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.